Gili Kenet
Gili Kenet is an expert in Hematology at Sheba Medical Center (Israel). As of October 2026, ScienceLeadR ranks Gili Kenet in the top 1% of experts worldwide for Hemophilia A and Embolism and Thrombosis. Gili Kenet has authored 447 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 1 of them ongoing. SLR score: 1,516 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Pediatrics - Genetics - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1995 - 2026
Number : 447
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Denecimig (Mim8) prophylaxis in children with hemophilia A with or without factor VIII inhibitors. PMID 42835127 — injections, quality of life, factor viii, antibodies, caregivers, drug-related side effects and adverse reactions, hemophilia a, therapeutics, child | Res Pract Thromb Haemost | 2026 | 0 |
| FVIII exposure, bleeding outcomes, and inhibitor development in 80 PUPs and MTPs with severe hemophilia A on emicizumab prophylaxis: real world data from the PedNet Registry. PMID 42448013 — registries, hemorrhage, drug-related side effects and adverse reactions, hemophilia a, thrombosis, infant | J Thromb Haemost | 2026 | 0 |
| Outcomes in venous thromboembolism with retained vs removed inferior vena cava filters: an analysis from the Registro Informatizado de Enfermedad TromboEmbólica. PMID 42436733 — registries, anticoagulants, mortality, vena cava filters, thromboembolism, hemorrhage, incidence, vena cava, inferior, venous thromboembolism | Res Pract Thromb Haemost | 2026 | 1 |
| Antiphospholipid syndrome in the paediatric population: performance of ACR-EULAR classification criteria in a controlled cohort. PMID 42373137 — classification, lupus erythematosus, systemic, antiphospholipid syndrome, diagnosis | Lupus Sci Med | 2026 | 1 |
| A Fragile Balance: Combined Thrombosis and Bleeding Disorders in Neonates. PMID 42134334 — hemorrhage, infant, newborn, critical illness, thrombosis, hemostasis | Semin Thromb Hemost | 2026 | 0 |
Clinical Studies 16
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 5
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors NCT04431726 — factor viii, safety, hemorrhage, parturition, caregivers, maintenance, hemophilia a, physicians, therapeutics, child, pharmacokinetics | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map